Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090227 · ClinicalTrials.gov registry record · Phase 1
AMPK-activation by Metformin in FSGS: AMP-FSGS
A Phase 1 study of Focal Segmental Glomerulosclerosis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06090227 is a Phase 1 study of Focal Segmental Glomerulosclerosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 235-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06090227, a Phase 1 study of Focal Segmental Glomerulosclerosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Conditions Studied
Interventions
- DRUG Metformin + Standard of Care
- OTHER Placebo + Standard of Care
Study Locations (2)
Connecticut
- Yale New Haven Hospital - New Haven
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06090227
The ClinicalTrials.gov registry entry for NCT06090227 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (87% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Metformin + Standard of Care is the first listed.
NCT06090227 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT06090227 about?
NCT06090227 is a clinical study titled "AMPK-activation by Metformin in FSGS: AMP-FSGS". The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
What is the current status of trial NCT06090227?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-12-14. Estimated completion is 2027-11.
What conditions does trial NCT06090227 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis.
What interventions are being tested in trial NCT06090227?
The interventions under investigation include: Metformin + Standard of Care (DRUG), Placebo + Standard of Care (OTHER).
Who is sponsoring clinical trial NCT06090227?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090227 being conducted?
This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Permeability Factor in Focal Segmental Glomerulosclerosis
COMPLETED · Phase 1
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
-
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 2
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 3
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.